Arnuity

PreclinicalSmall molecule

GSK

Arnuity is one of 20 small molecule programs targeting Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Formoterol Fumarate

AstraZeneca

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

2 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 9

Ozone

TTanta University

Preclinical

1 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Therapeutics

NCT03002389

Clinical

Trials by Indication[1]

Drug1 trial

Arnuity® Ellipta® Drug Use Investigation

Completed· GSK logo

GSK··NCT03184480·336 enrolled

Therapeutics1 trial

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Active, not recruiting·UUniversity of Virginia·Phase 2·NCT03002389·95 enrolled

Asthma1 trial

Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting

Completed· GSK logo

GSK··NCT03595930·668 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Arnuity. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arnuity compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arnuity. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Arnuity

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Drug1 trial

Therapeutics1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News